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Dermatologic Toxicity Occurring During
Anti-EGFR Monoclonal Inhibitor Therapy in
Patients With Metastatic Colorectal Cancer: A
Systematic Review
Mario E. Lacouture,1 Milan Anadkat,2 Aminah Jatoi,3 Tamer Garawin,4
Chet Bohac,4 Edith Mitchell5
Abstract
Monoclonal antibody inhibitors of the epidermal growth factor receptor (EGFR) have been shown to improve outcomes
for patients with metastatic colorectal cancer (mCRC) without RAS gene mutations. However, treatment with anti-
EGFR agents can be associated with toxicities of the skin, nails, hair, and eyes. Because these dermatologic toxic-
ities can result in treatment discontinuation and affect patient quality of life, their management is an important focus
when administering anti-EGFR monoclonal antibodies. The present systematic review describes the current data
reporting the nature and incidence of, and management and treatment options for, dermatologic toxicities occurring
during anti-EGFR treatment of mCRC. A search of the National Library of Medicine PubMed database from January 1,
2009, to August 18, 2016, identiﬁed relevant reports discussing dermatologic toxicity management among patients
with mCRC receiving anti-EGFR therapy. The studies were grouped by type and rated by level of evidence using the
GRADE approach developed by the Agency for Healthcare Research and Quality. Overall, 269 reports were reviewed
(nonrandomized trials, n ¼ 120; randomized trials, n ¼ 31; retrospective studies, n ¼ 15; reviews, n ¼ 39). Derma-
tologic toxicity of any grade occurs in most patients who receive anti-EGFR therapy; approximately 10% to 20% of
patients experienced grade 3/4 toxicity. The most common dermatologic toxicities include papulopustular/acneiform
rash, xerosis, and pruritus; however, nail changes, hair abnormalities, and ocular conditions also occur. Guidance for
managing these toxicities includes the use of inexpensive emollient ointments and moisturizers, avoidance of sun
exposure, avoidance of irritants, and the use of short showers. Several studies also found that preemptive treatment
was more effective than reactive treatment at limiting the incidence and severity of skin toxicity. With appropriate
treatment, the dermatologic toxicities associated with anti-EGFR monoclonal antibody therapy can be managed,
minimizing patient discomfort and the need for therapy interruption and/or discontinuation. Additionally, preemptive
treatment can reduce dermatologic toxicity severity, ultimately yielding better quality of life.
Clinical Colorectal Cancer, Vol. 17, No. 2, 85-96 ª 2018 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Introduction
Activation of the epidermal growth factor receptor (EGFR), a cell-
surface, tyrosine kinase receptor, results in receptor dimerization and
tyrosine autophosphorylation, which mediates cell survival, prolifer-
ation, angiogenesis, and tumor invasiveness in colorectal cancer
(CRC).1 Monoclonal antibody inhibitors of the EGFR have been
shown to improve outcomes in patients with CRC.2-5 Two mono-
clonal anti-EGFR antibodies, panitumumab and cetuximab, have
been approved by the US Food and Drug Administration and the
EuropeanMedicines Agency for the treatment of certain patients with
metastatic CRC (mCRC).6-9Others are currently under investigation
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(eg, nimotuzumab,10 necitumumab,11 imgatuzumab12). Pan-
itumumab, a fully human anti-EGFR monoclonal antibody, and
cetuximab, a chimeric anti-EGFR monoclonal antibody, have
demonstrated efﬁcacy in patients with wild-type KRAS CRC in the
ﬁrst-, second-, and third-line settings asmonotherapies and combined
with chemotherapy.4,5,13-16 Determining KRAS status and, more
recently,RAS status (ie,KRAS exon 2, 3, 4, andNRAS exons 2, 3, 4), is
extremely important in CRC because patients with mutated, consti-
tutively active RAS will not respond to panitumumab or cetuximab
therapy.5,14-20 The current guidelines from the National Compre-
hensive Cancer Network and European Society of Medical Oncology
recommend the use of panitumumab and cetuximab as appropriate
options for patients with wild-type RAS mCRC and recommend the
use of extended RAS testing for all patients before receiving treatment
with these anti-EGFR antibodies.21,22
Treatment with anti-EGFR agents has been associated with a
number of dermatologic toxicities (including skin rash, abnormal
hair growth, ocular abnormalities). These toxicities can occur
frequently: w90% of patients will experience skin toxicity of any
grade during treatment with panitumumab or cetuximab mono-
therapy, although most events will be grade 1 or 2 in severity2,23 and
rarely life-threatening. In a systematic review of 8998 patients with
cancer, no deaths were attributed to dermatologic toxicity.24
However, because these toxicities can result in treatment discon-
tinuation and can potentially affect a patient’s emotional and
physical well-being, their management should be an important
focus when administering these agents.25 Guidance on the man-
agement of skin toxicity occurring during treatment with EGFR
inhibitors in patients with cancer was reported in 2009.25
Since 2009, the methods for treatment of mCRC with anti-EGFR
antibodies have changed because of important developments in the
management of such skin toxicity and changes in the clinical use of
anti-EGFR monoclonal antibodies. Anti-EGFR therapy was initially
approved as third-line therapy2,23; however, subsequent approvals for
use as ﬁrst- and second-line therapy and combined with chemo-
therapy have occurred in the United States, Europe, Canada, and
other localities.7,9,26,27 Evidence has also shown that the incidence
and severity of dermatologic toxicity can be inﬂuenced by the addition
of chemotherapy.2,4,5,23,28 New approaches to the management of
skin toxicity have been used, such as the introduction of novel ther-
apeutic agents and the use of preemptive treatment approaches based
on the regimens evaluated in the STEPP (Skin Toxicity Evaluation
Protocol with Panitumumab) and J-STEPP (randomized controlled
trial on the skin toxicity of panitumumab in Japanese patients with
metastatic colorectal cancer: HGCSG1001 study) randomized
studies, which showed that preemptive treatment resulted in a
reduced incidence of skin toxicity compared with reactive treat-
ment.29,30 Furthermore, new evidence has shown associations be-
tween skin toxicity and both efﬁcacy outcomes31 and patient quality
of life.32,33 Given these changes, an updated report providing infor-
mation on themanagement of dermatologic toxicity during treatment
with anti-EGFR inhibitors in patients with mCRC would be of sig-
niﬁcant value. To address this need, we conducted a systematic review
of recent data to examine the types and frequencies of dermatologic
toxicities associated with anti-EGFR therapies and to explore the




A search of the National Library of Medicine PubMed database
was performed to identify relevant data discussing the management
of dermatologic toxicities associated with the use of anti-EGFR
therapies in the treatment of mCRC and the association between
toxicity and patient outcomes. The lower limit date of the search
was set at January 1, 2009, to capture studies reported after the
2009 Journal of the National Comprehensive Cancer Network publi-
cation. The upper limit date was set at August 18, 2016. Search
terms were selected that would capture studies addressing anti-
EGFR therapies, CRC, dermatologic toxicity, or treatment of
dermatologic toxicity (Table 1).
Data Collection and Analysis
Studies were selected for inclusion in the systematic review if they
reported the incidence of dermatologic toxicity, treatment options,
guidelines or recommendations for managing dermatologic toxicity, or
an association between dermatologic toxicity and patient outcomes. All
of us participated in the study selection and review. The studies were
grouped by type (eg, randomized trials, nonrandomized trials, case re-
ports, medical record reviews or case studies, economic analyses, letters
to the editor, systematic reviews ormeta-analyses, observational studies,
preclinical studies, retrospective reviews, and reviews). The reports were
rated by the level of evidence using theGRADE approach developed by
the Agency for Healthcare Research and Quality.34
Review
Using the deﬁned criteria, a total of 347 reports were obtained for
review. We excluded 34 studies because they had been reported in a
language other than English and 44 because they did not meet the
article inclusion criteria. Overall, 269 reports were reviewed for the
present analysis (Figure 1).
Incidence of Dermatologic Toxicities
Dermatologic toxicity of any grade occurs in most patients who
receive anti-EGFR therapy, and w10% to 20% of patients will
experience grade 3/4 toxicity.4,15,35,36 The overall incidence of grade
3/4 skin toxicity was greater in phase III studies of anti-EGFR
therapy combined with either 5-ﬂuorouracil, leucovorin, and irino-
tecan (FOLFIRI; CRYSTAL, 20050181) or 5-ﬂuorouracil,
leucovorin, and oxaliplatin (FOLFOX; Panitumumab Randomized
Trial in Combination with Chemotherapy for Metastatic Colorectal
Cancer to Determine Efﬁcacy [PRIME], Oxaliplatin and Cetuximab
in First-line Treatment of mCRC [OPUS]; 18%-35%) compared
with EGFR inhibitor monotherapy (20020408, A Study of Pan-
itumumab Efﬁcacy and Safety Compared to Cetuximab
[ASPECCT], 20100007; < 15%).3,4,28,36,37 The results from the
ASPECCT study indicated that the incidence, severity, and nature of
dermatologic toxicity occurring with either panitumumab or cetux-
imab treatment are generally similar.36 The most frequent grade 1/2
skin-related toxicities that occurred in the panitumumab and
cetuximab arms were skin rash (45.4% vs. 47.4%), dermatitis
acneiform (24.4% vs. 24.3%), dry skin (16.5% vs. 15.7%), pruritus
(ie, severe itching; 15.9% vs. 17.3%), paronychia (9.5% vs. 12.9%),
and acne (9.9% vs. 12.7%). Few patients had grade  3 skin-related
toxicities (Table 2).
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Skin Rash and Dermatitis. The most common dermatologic
toxicity associated with the use of anti-EGFR inhibitors is a pap-
ulopustular/acneiform rash, which, if it occurs, will usually appear
within the ﬁrst 1 to 2 weeks of initiating anti-EGFR therapy.25 The
Common Terminology Criteria for Adverse Events (CTCAE),
version 4.0, grades skin rash using a scale from 1 to 4.38 Grading the
severity of skin toxicity using the CTCAE considers the physical
manifestations of these events, in addition to their psychosocial
impact, effect on activities of daily living, and the need for intra-
venous antibiotics (Figure 2). In addition to rash, xerosis (ie, rough,
dry skin; Figure 3A) and pruritus (ie, severe itching sensation of the
skin that provokes the need to scratch) are common occurrences.
The ﬁrst symptoms of xerosis typically occur within 1 to 2 months
of the initiation of therapy, and pruritus usually develops 2 to 3
weeks after the initiation of anti-EGFR therapy.39 In most cases,
pruritus will be mild or localized and can be managed with topical
intervention, with very few patients experiencing grade  3 pruri-
tus. However, even in these instances, pruritus can affect patients’
quality of life and activities of daily living (Table 2).36
Nail Changes. Paronychia, an inﬂammation of the nail folds of
the ﬁngernails and toenails, can lead to infection, and the conse-
quent swelling and tenderness often affect patients’ activities of daily
living (Figure 3B). Paronychia typically develops after skin re-
actions, usually within 20 days to 6 months of initiating anti-EGFR
treatment.25 Approximately 10% to 30% of patients experience
paronychia during anti-EGFR therapy.40-44
Hair Abnormalities. Because the EGFR is expressed in both the
keratinocytes of the epidermis and at the root of hair follicles, anti-
EGFR therapies can also affect hair growth.25 Most hair-growth ab-
normalities associated with anti-EGFR therapies occur on the scalp or
eyelashes; however, hair abnormalities vary with body location and
among individuals.25 Treatment with anti-EGFR therapies can cause
both scalp and body alopecia and can also cause trichomegaly, a rare
condition in which the eyelashes grow long and curl inward. Tri-
chomegaly will occur in approximately 30% of patients.40
Ocular Conditions. The EGFR is also expressed on the eye surfaces
and in the tear and sebaceous glands; thus,  15% of patients
receiving anti-EGFR therapy can experience ocular toxicity.45 Among
the patients who develop these issues, the most frequent include
foreign body sensations (38%), dryness (32%), itchiness (28%), rash
(22%), redness (14%), eyelash changes (12%), blurry vision (7%),
tearing (6%), burning (3%), and photophobia (3%).45 Additionally,
conjunctivitis has been reported inw6% to 20% of patients.40
Management of Dermatologic Toxicities
Avariety of treatment options and approaches have been shown tobe
effective in the management of the dermatologic toxicities associated
with anti-EGFR therapy in patients with mCRC. Guidance for the
management of speciﬁc dermatologic toxicities, considering both the
nature and severity of the event, is provided in the subsequent sections.
In general, for patients who develop mild to moderate (ie, grade
1/2) skin reactions, these skin-related toxicities are commonly
managed with inexpensive emollient ointments and moisturizers,
the avoidance of sun exposure,46-48 avoidance of the use of irri-
tants,47-51 and the use of short showers. Patients should avoid
alcohol-based or perfumed products because they can dry the
skin47-51 and limit the skin’s ability to heal by keeping it in a state of
stress. However, the use of alcohol-free products that contain
esteriﬁed alcohols (eg, cetyl, stearyl, and cetaryl alcohols) that do not
irritate the skin can be effective.52 In patients with moderate to
severe skin toxicities, application of topical steroid creams, such as
hydrocortisone (0.5%-2.5%), alone or combined with topical
emollients and moisturizers, can be required.29,48,53,54 In instances
in which the dermatologic skin toxicity leads to infection, topical
antibiotic ointments or systemic antibiotics must also be given.53,54
Table 1 Literature Review Search Terms
(Vectibix [tiab] OR panitumumab [tiab] OR ABX-EGF [tiab] OR Panitumumab [nm] OR Erbitux [tiab] OR cetuximab [tiab] OR IMC-C225 [tiab] OR Cetuximab [nm] OR
nimotuzumab [tiab] OR Theracim [tiab] OR Theraloc [tiab] OR “BIOMAb EGFR” [tiab] OR matuzumab [tiab] OR “EMD 72000” [tiab] OR zalutumumab [tiab] OR EGFR [tiab]
OR HuMax-EGFR [tiab])
AND
(Colorectal [tiab] OR colon [tiab] OR rectum [tiab] OR rectal [tiab] OR colonic [tiab])
AND
(skin [tiab] OR rash [tiab] OR integument [tiab] OR dermatitis [tiab] OR stomatitis [tiab] OR pruritus [tiab] OR papulopustular [tiab] OR acne [tiab] OR “dry skin” [tiab] OR
eczema [tiab] OR nail [tiab] OR erythrodysesthesia [tiab] OR erythrodysaesthesia [tiab] OR erythema [tiab] OR paronychia [tiab] OR eye [tiab] OR retina [tiab] OR Acanthosis
[tiab] OR acne pustular [tiab] OR angiokeratoma [tiab] OR blister [tiab] OR capillaritis [tiab] OR cataract [tiab] OR cellulitis [tiab] OR chorioretinitis [tiab] OR conjunctivitis
[tiab] OR corneal [tiab] OR acneiform [tiab] OR herpetiformis [tiab] OR psoriasiform [tiab] OR eosinophilia [tiab] OR dry eye [tiab] OR dry skin [tiab] OR endophthalmitis [tiab]
OR exfoliative [tiab] OR eye pruritus [tiab] OR eyelash thickening [tiab] OR eyelids pruritus [tiab] OR hyperkeratosis [tiab] OR keratitis [tiab] OR nail bed inﬂammation [tiab]
OR nail psoriasis [tiab] OR optic neuropathy [tiab] OR palmar erythema [tiab] OR palmar-plantar erythrodysaesthesia syndrome [tiab] OR palmar-plantar erythrodysesthesia
syndrome [tiab] OR perivascular dermatitis [tiab] OR petechiae [tiab] OR plantar erythema [tiab] OR psoriasis [tiab] OR pustular psoriasis [tiab] OR rash papular [tiab] OR
papulosquamous [tiab] OR pruritic [tiab] OR rash pustular [tiab] OR xeroderma [tiab] OR retinitis [tiab] OR exfoliation [tiab] OR photosensitivity [tiab] OR onycholysis [tiab]
OR maceration [tiab] OR erythematous [tiab] OR hair [tiab] OR ulceration [tiab] OR alopecia [tiab] OR folliculitis [tiab] OR maculo-papular [tiab] OR “vision blurred” [tiab] OR
“blurred vision” [tiab] OR cheilitis [tiab] OR excoriation [tiab] OR hypertrichosis [tiab] OR hyperpigmentation [tiab] OR urticaria [tiab] OR conjunctival [tiab] OR “eye swelling”
[tiab] OR hirsutism [tiab] OR “ingrowing nail” [tiab] OR “lip dry” [tiab] OR onychoclasis [tiab] OR papule [tiab] OR pigmentation [tiab] OR scab [tiab] OR xerosis [tiab] OR
abscess [tiab] OR ﬁssure [tiab] OR eyelid [tiab] OR eyes [tiab] OR nails [tiab] OR eyelashes [tiab] OR hordeolum [tiab] OR dermal [tiab] OR intertrigo [tiab] OR macular [tiab]
OR ocular [tiab] OR onychomadesis [tiab] OR onychomycosis [tiab] OR otitis [tiab] OR periorbital [tiab] OR seborrhoea [tiab] OR seborrhoeic [tiab] OR purpura [tiab] OR
sunburn [tiab] OR retinopathy [tiab] OR dermatologic [tiab] OR dermatology [tiab] OR dermatologist [tiab] OR soap [tiab] OR cream [tiab] OR “topical steroid” [tiab] OR
hydrocortisone [tiab] OR moisturizer [tiab] OR sunscreen [tiab] OR Lubriderm [tiab] OR PABA [tiab] OR SPF [tiab] OR doxycycline [tiab] OR “hair changes” [tiab] OR)
AND
(“2009/01/01"[PDAT]: ”2016/8/18“[PDAT]”)
Abbreviations: nm ¼ supplementary concept; PDAT ¼ publication date; Tiab ¼ title or abstract.
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In circumstances in which the toxicity is moderate to severe
(grade 3/4 events), referral of the patient to a dermatologist is rec-
ommended because the dermatologist will have more knowledge
and experience treating the more severe dermatologic ailments.
However, if this is not practical or expedient, the patient’s primary
provider might be able to determine the type of treatment required
to manage dermatologic toxicity. Referral to a dermatologist is also
recommended in cases in which the toxicity does not improve
within 1 to 2 weeks, if the patient is having difﬁculty managing
more severe skin toxicity and is considering stopping EGFR
inhibitor treatment, and in cases in which the patient is severely
symptomatic (ie, if necrosis, bleeding, or petechial or purpuric
lesions are present or if the skin toxicity has an uncharacteristic
appearance or distribution).48
Preemptive Versus Reactive Management of Skin Toxicity. Measures
for managing dermatologic toxicity can be taken either
before administering anti-EGFR monoclonal antibody therapy
Figure 1 Types of Studies Included in the Systematic Review
Abbreviations: CRC ¼ colorectal cancer; EGFR ¼ epidermal growth factor receptor; mAbs ¼ monoclonal antibodies.
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(ie, preemptive treatment) or after symptoms have occurred (ie,
reactive treatment). Several studies have examined the effect of
preemptive versus reactive treatment regimens on the incidence and
severity of skin toxicity.29,30,53 The largest of these trials was the
STEPP (Skin Toxicity Evaluation Protocol with Panitumumab) and
HGCSG1001 (J-STEPP) studies.
The STEPP trial was a phase II, open-label, randomized trial
that evaluated the effect of preemptive versus reactive treatment
regimens on skin toxicity management for patients treated with
panitumumab combined with irinotecan or FOLFIRI.30 Pre-
emptive treatment was administered beginning on day 1 and
continued for weeks 1 to 6. Preemptive treatment consisted of the
use of a skin moisturizer (applied to the face, hands, feet, neck,
back, and chest daily in the morning), sunscreen (applied before
going outdoors), topical steroids (1% hydrocortisone cream
applied to the face, hands, feet, neck, back, and chest daily in the
evening), and oral doxycycline (100 mg, taken twice daily).30
Reactive treatment consisted of any treatment deemed appro-
priate by the investigator and could be administered during weeks
1 to 6.30 The results from the STEPP trial showed the incidence
of grade  2 skin toxicities was 29% among patients who received
preemptive treatment compared with 62% in the reactive group
(odds ratio, 0.3; 95% conﬁdence interval [CI], 0.1-0.6).30 Six
percent of patients in the preemptive arm developed grade 3/4
skin toxicity compared with 21% in the reactive group. Efﬁcacy
was similar between the 2 groups: 7 patients (15%) in the
preemptive group had a partial response compared with 5 patients
(11%) in the reactive group. Also, the stable disease rate was
similar between the 2 groups (50% vs. 53%).30 Furthermore, the
median progression-free survival (PFS) time was 4.7 months (95%
CI, 2.9-6.0) in the preemptive group and 4.1 months (95% CI,
2.9-6.2) in the reactive group (hazard ratio [HR], 1.0; 95% CI,
0.6-1.6).30
The J-STEPP study was a phase III, open-label, randomized trial
that evaluated the differences between preemptive and reactive
treatment in skin toxicity management in Japanese patients with
mCRC. A central review of skin toxicities was also performed by a
single dermatologist, using photographs that were taken at every ofﬁce
visit.29 The treatments used were similar to those in the STEPP study.
Preemptive treatment consisted of a skin moisturizer and topical
steroid (0.5% hydrocortisone cream applied to the face, hands, feet,
neck, back, and chest twice daily morning and evening), sunscreen
(applied to sun-exposed areas before going outside), and minocycline
(100 mg, once daily).29 Reactive treatment consisted solely of a skin
moisturizer, although the use of sunscreen was permitted if requested
by the patient.29 The results indicated the cumulative incidence of
grade 2 skin toxicities in 6 weeks was 21.3% (95%CI, 9.6-33.0) in
the preemptive treatment group compared with 62.5% (95% CI,
48.8-76.2) in the reactive treatment group (relative risk, 0.34; 95%
CI, 0.19-0.62; P< .001). Similar incidence trends were observed at 8
and 12 weeks.29 Two percent of patients in the preemptive arm and
15% in the reactive arm developed grade 3/4 skin toxicity.29 No
statistically signiﬁcant differences were found in PFS (HR, 1.20; 95%
CI, 0.78-1.84; P ¼ .413), overall survival (OS; HR, 1.19; 95% CI,
0.75-1.90; P ¼ .469), or the objective response rate (ORR; pre-
emptive, 13.3%; reactive, 18.2%; P ¼ .530) were observed between
the 2 groups.29
In both the STEPP30 and J-STEPP29 studies, skin toxicity
symptoms and treatment compliance were documented by patients
using daily diaries, and this information was used by the in-
vestigators to complete case report forms. Because these data were
self-reported daily by patients, the possibility exists that an inherent
bias could have been introduced and that the patients’ mental state
or level of overall physical health could have affected their
perception of the severity of their symptoms. Thus, this approach
might have resulted in a greater recorded overall incidence of skin
Table 2 Incidence of Dermatologic Toxicity Among Patients Receiving Panitumumab or Cetuximab in the ASPECCT Study
Variable
Panitumumab (n [ 496) Cetuximab (n [ 503)





368 (74.2) 60 (12.1) 2 (0.4) 392 (77.9) 48 (9.5) 0 (0.0)
Skin toxicity adverse
events in > 5% of
patients in either
treatment arm
Rash 225 (45.4) 23 (4.6) 1 (0.2) 239 (47.5) 18 (3.6) 0 (0.0)
Dermatitis
acneiform
121 (24.4) 17 (3.4) 0 (0.0) 122 (24.3) 14 (2.8) 0 (0.0)
Dry skin 82 (16.5) 1 (0.2) 0 (0.0) 79 (15.7) 0 (0.0) 0 (0.0)
Pruritus 79 (15.9) 4 (0.8) 0 (0.0) 87 (17.3) 1 (0.2) 0 (0.0)
Paronychia 47 (9.5) 11 (2.2) 0 (0.0) 65 (12.9) 10 (2.0) 0 (0.0)
Acne 49 (9.9) 3 (0.6) 0 (0.0) 64 (12.7) 5 (1.0) 0 (0.0)
Skin ﬁssures 41 (8.3) 1 (0.2) 0 (0.0) 40 (8.0) 3 (0.6) 0 (0.0)
Nail disorder 25 (5.0) 1 (0.2) 0 (0.0) 29 (5.8) 2 (0.4) 0 (0.0)
Data presented as n (%).
aIncluding adverse events in the “Skin and Subcutaneous Tissue Disorders” system organ class of the Medical Dictionary for Regulatory Activities, version 15.1.
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toxicity compared with the more objective investigator assessments
of toxicity typically used in clinical trials. The results from these
studies indicated that preemptive treatment can reduce the inci-
dence of skin toxicity during treatment with panitumumab without
altering antitumor efﬁcacy. Together, these data indicate that the
use of a preemptive management regimen can decrease the occur-
rence and severity of dermatologic toxicity resulting from
anti-EGFR therapy with no signiﬁcant effects on treatment efﬁcacy.
The recommended preemptive treatments for dermatologic toxicity
include avoidance of sun exposure, hydrocortisone combined
with moisturizers, the daily use of sunscreen, doxycycline, mino-
cycline, oral antibiotics, corticosteroid creams, and/or oatmeal
baths.29,30,46,47,53,54
Skin Rash and Dermatitis. The treatments commonly used for the
management of skin rash are detailed in Table 3. The reported data
have described treatment of patients with grade 1 or 2 skin rash to
include petrolatum emollients, medium- to high-potency topical
corticosteroids, oral minocycline or doxycycline, 0.5% to 2.5%
hydrocortisone cream, H1 antihistaminic loratadine, and saline/
boric acid compresses.40,51,55-59 Topical antibiotics such as clinda-
mycin, erythromycin, and metronidazole and benzoyl peroxide can
be used to treat skin toxicities; however, these are usually avoided in
patients with papulopustular or acneiform eruption because these
treatments have drying properties that can induce rosacea and can
be irritating.40,60 Additionally, the use of topical retinoids is typi-
cally avoided because of their greater potential for irritation.57
Figure 2 Photographs of Skin Rash Occurring During Anti-epidermal Growth Factor Receptor Monoclonal Antibody Treatment
According to Body Location and Grade. Grade 1 Skin Rash Is Deﬁned as Papules/Pustules Covering < 10% of the Body. Grade
2 Skin Rash Is Deﬁned as Papules/Pustules Covering 10% to 30% of the Body and Is Associated With Psychosocial Effects
and Limiting Daily Life. Grade 3 Rash Is Deﬁned as Papules/Pustules Covering > 30% of the Body That Limit Daily Life and
Are Associated With Local Superinfection Requiring Oral Antibiotics
Anti-EGFR Dermatologic Toxicity Literature Review
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Patients are cautioned to avoid sunbathing, direct sunlight, hot
temperatures, and humidity.48,58,59,61 Patients should avoid
manipulation of skin or hot blow-drying of the hair because these
can increase the risk of infection.39 Although the use of greasy
creams such as petroleum jelly is highly effective, the treatment can
cause folliculitis owing to its occlusive properties.
For patients with grade 3/4 skin rash, the reports most commonly
suggested temporary dose interruption and/or reduction of anti-
EGFR therapy, depending on the severity of the rash and the
patient’s tolerance level.47,54,56,61,62 In addition to the suggested
reductions, other possible recommended treatment methods include
the administration of doxycycline; minocycline; oral; intramuscular;
intravenous antihistamine; high-dose tetracycline; oral corticoste-
roids (methylprednisolone, prednisone); oral retinoids (low-dose
isotretinoin); or intravenous antibiotics.47,56,57,61
Treatment of xerosis and/or pruritus often includes the use of
moisturizers or oral antihistamines.57,58 Emollients and cyanoacry-
late tissue adhesives can effectively treat xerosis but must be used
with care because their occlusive properties can lead to follicu-
litis.63,64 For patients who experience eczema, treatment with
cortico steroids is recommended; for those who experience eczema
with blisters (wet eczema), cultures should be conducted to ensure
no bacterial or viral infection is present.64
Nail Changes. When monitoring for paronychia or ﬁssures, it is
important to begin careful inspections of the hands and feet early
during treatment and to continue these inspections at every clinic
visit. If nail abnormalities are identiﬁed, the treatments described
included antibacterial emollient applied regularly, corticosteroid
ointments, or a white vinegar in water solution (1 part vinegar, 1
Figure 3 Photographs of (A) Xerosis and (B) Paronchyia Occurring During Anti-Epidermal Growth Factor Receptor (EGFR) Therapy by
Grade. The First Symptoms for Xerosis (ie, Rough, Dry Skin) Typically Occur Within 1 to 2 Months of Initiation of anti-EGFR
Therapy. Paronchyia (ie, Inﬂammation of the Nail Folds of the Fingernails and Toenails) Can Lead to Infection and
Swelling/Tenderness and Usually Develops After Skin Reactions, Within 20 Days to 6 Months After Treatment Initiation
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part water).61,65 Other suggested treatments for paronychia include
the use of gentamycin ointment for 4 to 5 weeks, bathing the hands
and/or feet in a diluted chloramine bath, and wearing loose-ﬁtting
shoes to avoid pressure to the nail beds.40,50 Preemptive daily
treatment with corticosteroids was shown to reduce the incidence of
paronychia in both the J-STEPP and STEPP studies.29,30
Hair Abnormalities. For the treatment of trichomegaly, the
reported data suggest trimming eyelashes that are long or curled
(usually by an ophthalmologist) and removing eyelashes that have
misdirected growth (again, usually by an ophthalmologist).40,45,61
For other hair and scalp problems, emollients, such as those used
for skin rash, and erythromycin ophthalmic ointments can be
used.40,51 Patients who experience an acneiform eruption on the
scalp can be treated with an oil bath and topical steroid therapy.40 If
the eruption is infected, an oil bath, followed by treatment with oral
antibiotics, has been recommended; topical antibiotics, such as
neomycin and bacitracin, are not effective in the treatment of scalp
infections.40,66 Hair stickiness can also be treated with an oil bath or
using mild shampoos.40
Ocular Conditions. The treatments for ocular conditions are
outlined in Table 4. For patients with a mild case of dry eye,
treatment with supplemental tears 4 to 6 times daily has been
suggested.45,54 For cases that are moderate to severe, the use of tear
ﬁlm or anti-inﬂammatory medication could be needed.45 For
patients who experience blepharitis (ie, eyelid margin inﬂamma-
tion), recent reports suggested treatment with lid scrubs and warm
compresses for 5 minutes twice daily for those with mild cases.45,54
Moderate cases might require treatment with an eye ointment,45
and severe cases could require treatment with doxycycline 50 mg
twice daily for 2 weeks, followed by 50 mg once daily for 4 weeks.45
For the treatment of eyelid hyperemia (vascular engorgement of
the eyelid), the reports suggested treating acute instances with
ﬂuorometholone (0.1%) 1 to 3 times daily for 1 week.45 For
chronic cases, treatment with tacrolimus (0.03%) ointment or
pimecrolimus cream twice daily might be required.45 For patients
who contract conjunctivitis, treatment of the eye with an
ophthalmic suspension of neomycin and polymyxin B sulfates and
dexamethasone for 14 days can be used.40 To treat patients who
develop telangiectasias (ie, dilation of the capillaries in the eye,
causing the appearance of small red or purple clusters), laser therapy
is advised.40
For all instances of ocular toxicity, patients should be referred to
an ophthalmologist if they experience persistent ocular pain, sig-
niﬁcant loss of vision or decreased acuity of vision, or severe redness
of the eye or light sensitivity.67 Patients should also be referred to a
specialist if they fail to respond within 1 week of treatment initiation
for squamous blepharitis, meibomitis, or dysfunctional tear
syndrome.67
Treatments Currently Under Investigation. Numerous new options
are currently under investigation for the management of derma-
tologic toxicities, and most of these treatments are targeted for the
treatment of skin rash. One treatment option, Abound, which is a
mixture of b-hydroxyl b-methyl butyrate, glutamine, and arginine,
is under investigation in Japan.68 Previously, Abound showed
activity for increasing the lean body mass in patients with cachexia
caused by cancer or rheumatoid arthritis.69,70 In a case report, the
use of Abound on the lower limbs of a patient receiving
anti-EGFR therapy resulted in a profound reduction in the extent
and severity of dermatologic toxicity after 1 month of continued
use.68
The use of phytomenadione cream (vitamin K1) for the treat-
ment of skin rash associated with anti-EGFR therapy is also under
investigation.59,71-73 A small case series (n ¼ 20) investigated the
application of phytomenadione cream as a pretreatment for anti-
EGFR therapy.71 Patients applied the cream twice daily during
the ﬁrst month of therapy, beginning the day before infusion, and
daily during the second month.71 Most patients (75%) only expe-
rienced mild grade 1 acneiform rash with pretreatment; the
remaining 25% experienced a grade 2 rash.71 No signs of toxicity or
intolerance were observed after the topical application, and no
changes in blood coagulation occurred.71 Another study (n ¼ 41)
found the application of phytomenadione cream twice daily resulted
in a low proportion of patients with grade 2 (25%) and grade 3
(15%) rash.72 Furthermore, a recent study (n ¼ 60) found that
applying the cream 3 times daily on the day of anti-EGFR
administration improved the skin itch and dry skin symptoms for
patients with mCRC.73
The use of bittim soap (made from the oil extracted from Pistacia
terebinthus fruits) for the treatment of skin toxicity is also being
assessed.74 In a small study (n ¼ 15) that evaluated the use of bittim
soap in the treatment of grade 2 or 3 toxicity, patients applied the
soap twice daily for 2 minutes and then rinsed for 1 week; the use of
topical or oral antibiotics, corticosteroids, or moisturizers was not
permitted.74 The complete response rate (ie, disappearance of all
toxicity) for patients with grade 2 or 3 toxicity was 100% and 33%,
respectively; the remaining patients with grade 3 toxicity improved
to grade 1 with treatment.74 Skin toxicity recurred when the use of
the soap was discontinued.74
Table 3 Management of Skin Rash Associated With
Anti-EGFR Therapies


















Menthol cream Oral or IV
antihistamines














Abbreviations: EGFR ¼ epidermal growth factor receptor; IV ¼ intravenous.
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Associations Among Skin Toxicity, Clinical Outcomes, and
Quality of Life
Association With Clinical Outcomes. The appearance of dermato-
logic toxicity is an on-target event for patients receiving anti-EGFR
therapy and direct evidence that EGFR is being inhibited to a
biologically meaningful extent. Because this inhibition is required
for an antitumor effect to occur, it has been hypothesized that the
appearance of dermatologic toxicity might be evidence of antitumor
activity. Early studies observed a correlation between better out-
comes and patients who developed dermatologic toxicity early after
treatment.75,76 Subsequently, numerous other studies (which have
been extensively reviewed previously31,48,77-81) also described posi-
tive associations between the severity of skin toxicity and outcomes,
such as the ORR, OS, PFS, and time to tumor progression, among
patients receiving cetuximab or panitumumab.82,83
Association With Quality of Life. The appearance of dermatologic
toxicity has the potential to severely affect a patient’s quality of life
and activities of daily living, possibly resulting in missed anti-EGFR
therapy doses, dose reductions, and/or the complete cessation of
therapy.
Using a dermatology-speciﬁc quality-of-life questionnaire (Skin-
dex-16) to evaluate the domains of symptoms, emotion, and
function, Rosen et al33 found that patients with advanced cancer
who experienced rash or pruritus associated with an anti-EGFR
therapy (cetuximab, panitumumab, erlotinib, geﬁtinib, or lapati-
nib) had higher scores across all 3 domains compared with patients
who had not received anti-EGFR therapy and did not experience
these events. In a subsequent study that used Skindex-16 to evaluate
the quality of life of patients who received anti-EGFR therapy, the
rash grade was signiﬁcantly associated with greater Skindex-16
scores, suggesting that the National Cancer Institute CTCAE
grade represents an appropriate tool for the assessment of skin
toxicity severity on patient quality of life.32
A number of other studies have evaluated the quality of life of
patients with and without skin toxicity but did not demonstrate a
direct association between skin toxicity and quality of life.76,84-86
However, most of the quality-of-life instruments used in these
studies were not designed to evaluate the inﬂuence of skin toxicity
on quality of life and might have lacked sensitivity for this
outcome.32,33 One study reported that 41% of patients treated with
anti-EGFR therapy showed psychological distress; however, no
signiﬁcant correlation was found between the appearance of skin
rash and psychological distress. However, the study also noted that
47% of the patients avoided social situations and going out, that
patients with a longer history of disease considered skin rash to be
part of coping with advanced cancer, and that patients can be
encouraged to continue treatment because the presence of a skin
rash is indicative of the response.87 Another study found that the
perceived severity of the skin reaction had a signiﬁcant inﬂuence on
the dermatologic health-related quality of life, as measured using the
Deutsches Instrument zur Erfassung der Lebensqualität bei Hau-
terkrankungen, and this perception remained stable throughout the
course of treatment.88 No signiﬁcant correlation was found between
the objective severity of the skin reaction and the Deutsches
Instrument zur Erfassung der Lebensqualität bei Hauterkrankungen
score.88 Furthermore, in 1 study, increased skin toxicity severity
during panitumumab treatment was associated with better quality
of life, as measured using the modiﬁed Dermatology Quality of Life
Index (mDLQI).76 This plainly paradoxical outcome might have
resulted from an association between skin toxicity severity and the
duration of therapy or an association between the biologic effect of
panitumumab and skin toxicity, with such associations resulting in
improved patient outcomes that potentially result in improvements
in aspects of quality of life that outweigh the inﬂuence of skin
toxicity.
Because maintaining patient morale is an important part of
cancer therapy, every opportunity should be taken to minimize the
potential effects of dermatologic toxicity on patients’ quality of life.
A few studies have indicated that the use of preemptive treatment
for managing dermatologic toxicity can improve patient quality of
life. In 1 study, after preemptive treatment, only 3 patients of 51
reported a moderate effect of skin toxicity on their overall quality of
life, as measured using the mDLQI.89 Similarly, the results from the
STEPP trial indicated a reduced mean mDLQI score for patients
who received preemptive treatment for dermatologic toxicity
compared with those receiving reactive treatment, indicating that
reducing the appearance of early skin reactions could have a sig-
niﬁcant effect on patient perceptions and morale.30
Costs Associated With Dermatologic Toxicity
Relatively few studies thus far have evaluated the costs associated
with developing dermatologic toxicity during anti-EGFR treatment.
However, 1 economic analysis noted that dermatologic toxicity
requiring inpatient treatment (eg, hospitalization) resulted in sub-
stantially greater costs (w$4500/event) than if the toxicity could be
Table 4 Management of Ocular Conditions Associated With Anti-EGFR Therapies
Severity Dry Eye Blepharitis Eyelid Hyperemia Conjunctivitis Telangiectasias
Mild or acute Supplemental tears 4-6
times QD
Lid scrubs and warm
compresses for 5 min BID
Fluorometholone (0.1%)

















Doxycycline 50 mg BID
(2 wk), 50 mg QD (4 wk)
Pimecrolimus cream BID
Abbreviations: BID ¼ twice daily; EGFR ¼ epidermal growth factor receptor; QD ¼ once daily.
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treated in the outpatient setting ($185/event).90 Furthermore, a
retrospective analysis found that little difference was present in the
costs of treatment for a grade 2 (range, 200V-295V) versus grade 3
(range, 159V-234V) rash; however, the cost for grade 1 rash was
minimal (no treatments were initiated).91 Together, these studies
suggest that appropriate management to reduce the severity of
dermatologic reactions (ie, using preemptive treatment) could
translate into substantial cost reductions for the patient, in addition
to the other beneﬁts of such an approach.
Discussion
In the present review, we described the management and treat-
ment options for dermatologic toxicity, which generally consist of
the application of topical moisturizers or corticosteroid creams for
lesser grade occurrences or the use of systemic treatments such as
oral antibiotics for more severe occasions. In addition to these
treatment options, patients should be counseled to avoid sun
exposure and excessive heat, to wear loose ﬁtting clothing and shoes,
and to use alcohol-free products that do not irritate the skin.
Recent studies have suggested that these treatment methods
appear to be more effective when applied as part of a preemptive
regimen rather than after skin toxicity has occurred. The results
from the STEPP and J-STEPP studies have indicated that the
patients who underwent preemptive treatment for dermatologic
toxicity had a lower incidence of grade  2 skin toxicity compared
with those who received reactive treatment (20%-30% vs. 60%),
with no signiﬁcant effect on efﬁcacy outcomes, including PFS, OS,
and ORR.29,30 Furthermore, preemptive therapy can also reduce the
incidence of diarrhea, dehydration, and neutropenia. Decreased
recruitment of neutrophils to the skin and maintenance of the
integrity of the skin might minimize the incidence of neutropenia
and dehydration.29,30 EGFR-induced diarrhea also has an inﬂam-
matory or infectious component that can be improved through use
of doxycycline therapy. Preemptive treatment with doxycycline
therapy might also play a role in reducing secondary dermatologic
infections.92
Recent retrospective analyses have shown that patients who
experienced more severe dermatologic toxicity or dermatologic
toxicity that occurred early after treatment had improved outcomes
compared with those who had less severe reactions or reactions that
occurred later after treatment, suggesting that the development of
skin toxicity might be indicative of a positive response to anti-EGFR
therapy. This association between skin toxicity and tumor outcomes
suggests potential predictive value exists for dermatologic toxicity in
patients with mCRC; however, this association is potentially
confounded by exposure. Patients who have received more anti-
EGFR inhibitor exposure are more likely to develop dermatologic
toxicity and also to have a tumor response; therefore, it is impossible
to be certain whether dermatologic toxicity is truly predictive of the
response or just correlated with the outcomes. Although the
development of dermatologic toxicity might be indicative of a
positive response and the development of toxicity has not been
directly associated with a poorer quality of life for these patients, the
proper management of this toxicity remains essential to minimize
patient discomfort during therapy.
The present systematic review was subject to limitations. The
analysis was limited to studies of CRC; reports of other cancer types
for which anti-EGFR therapies are used or those for which the
cancer type was not speciﬁed were not included. Additionally,
studies that were not reported in peer-reviewed journals (ie, have
only been presented at conferences) or that were reported in journals
that are not indexed in PubMed were not included. Furthermore,
this search was limited to studies reported in English.
Conclusion
With appropriate treatment, dermatologic toxicities associated
with anti-EGFR therapies can be managed, minimizing patient
discomfort and reducing the need for therapy interruption or
discontinuation. Furthermore, the preemptive treatment of patients
can reduce the severity of dermatologic toxicities that result from
anti-EGFR therapy, ultimately leading to a better patient quality of
life.
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